Another piece of the evidence puzzle: is prostate-specific membrane antigen PET–CT a valuable tool for risk stratification?
The Lancet Medical Imaging & Theranostics · 2026
DOI: 10.1016/j.lanmit.2026.100008 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Medical Imaging & Theranostics, 2026. Verfasst von Armin Atzinger und 1 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A post-hoc analysis of the randomised phase 3 RAPID trial, published in The Lancet Medical Imaging & Theranostics by Holger Einspieler and colleagues, provides important prospective evidence regarding the use of prostate-specific membrane antigen (PSMA) PET–CT in detecting clinically significant primary prostate cancer.1 As molecular imaging is increasingly expanding beyond conventional tumour staging toward refined disease characterisation and individualised treatment stratification, these findings represent a step toward personalised, evidence-based medicine.
Zitieren
APA
Atzinger, A., & Rosar, F. (2026). Another piece of the evidence puzzle: is prostate-specific membrane antigen PET–CT a valuable tool for risk stratification?. The Lancet Medical Imaging & Theranostics. https://doi.org/10.1016/j.lanmit.2026.100008
Vancouver
Atzinger A, Rosar F. Another piece of the evidence puzzle: is prostate-specific membrane antigen PET–CT a valuable tool for risk stratification?. The Lancet Medical Imaging & Theranostics. 2026. doi:10.1016/j.lanmit.2026.100008
BibTeX
@article{Atzinger2026,
author = {Atzinger, Armin and Rosar, Florian},
title = {Another piece of the evidence puzzle: is prostate-specific membrane antigen PET–CT a valuable tool for risk stratification?},
journal = {The Lancet Medical Imaging & Theranostics},
year = {2026},
doi = {10.1016/j.lanmit.2026.100008}
}
EUVIMED